Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.
Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.
In August the National Institute for Health and Care Excellence (NICE) rejected the Swiss drugmaker's drug Kadcyla for an aggressive form of breast cancer. Roche had proposed a discount for that drug, which carries a full list price of more than 90,000 pounds for a course of treatment.
Friday's decision promises to further sour relations between NICE and the world's biggest maker of cancer drugs, which two months ago said NICE was "not fit for purpose".
Read the report on Reuters: http://reut.rs/1CIwReZ
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
FDA Approves Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer
February 3rd 2023The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Read More
2 Clarke Drive
Cranbury, NJ 08512